SFM
TVRD

Sphera Funds Management’s Tvardi Therapeutics TVRD Stock Holding History

Sphera Funds Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,443
Closed -$5.96M – 112
2019
Q1 		$5.96M Hold
8,443
– – 0.54% 41
2018
Q4 		$3.95M Buy
8,443
+1,334
+19% +$861K 0.45% 51
2018
Q3 		$6.13M Buy
+7,109
New +$5.13M 0.7% 35
2016
Q1 		– Sell
-5,495
Closed -$3.33M – 124
2015
Q4 		$3.33M Sell
5,495
-611
-10% -$335K 0.49% 49
2015
Q3 		$3.14M Buy
6,106
+4,809
+371% +$3.22M 0.4% 54
2015
Q2 		$567K Buy
+1,297
New +$501K 0.06% 123

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Sphera Funds Management's TVRD Position: Q2 2019 in Review

Sphera Funds Management sold out of Tvardi Therapeutics (TVRD) in Q2 2019, closing a stake of 8,443 shares — an estimated $5.96M sold.

Sphera Funds Management first reported a position in TVRD in Q2 2015 and held it in 6 quarters. The position peaked at $6.13M in Q3 2018. 126 funds tracked by Wall St. Rank hold TVRD as of Q2 2019.

  • Sphera Funds Management reported no remaining Tvardi Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Sphera Funds Management sold 8,443 Tvardi Therapeutics shares in Q2 2019, an estimated $5.96M.
  • Sphera Funds Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 6 quarters.
  • Sphera Funds Management's Tvardi Therapeutics position peaked at $6.13M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2019.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.